Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19135
Full metadata record
DC FieldValueLanguage
dc.contributor.authorThapa, Bibhusal-
dc.contributor.authorWalkiewicz, Marzena-
dc.contributor.authorMurone, Carmel-
dc.contributor.authorAsadi, Khashayar-
dc.contributor.authorDeb, Siddhartha-
dc.contributor.authorBarnett, Stephen A-
dc.contributor.authorKnight, Simon R-
dc.contributor.authorMitchell, Paul L R-
dc.contributor.authorLiew, Danny-
dc.contributor.authorWatkins, D Neil-
dc.contributor.authorJohn, Thomas-
dc.date2016-10-22-
dc.date.accessioned2018-09-13T00:21:05Z-
dc.date.available2018-09-13T00:21:05Z-
dc.date.issued2016-12-
dc.identifier.citationPathology 2016; 48(7): 660-665en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19135-
dc.description.abstractMalignant mesothelioma (MM) continues to be a disease with poor prognosis and limited treatment options. Calretinin and caveolin-1 expression by tumour in MM have recently been described to be associated with tumour histology, differentiation and consequently survival. In a large, well annotated cohort, we studied both of these biomarkers and explored their association with clinicopathological parameters and survival. A retrospective search of patients with MM who underwent surgery at the Austin Hospital in Melbourne, Australia, was conducted. Clinical history and outcome data were retrieved from patient records. Tissue microarrays (TMAs) were constructed and stained for calretinin and caveolin-1. 'H scores' were derived, taking intensity and distribution of staining, and the cohort was dichotomised using median values for both markers. In the 329 patients evaluated, median age was 67 years. Males outnumbered females by 5:1. Epithelioid histology 202/319 (62.9%) was the most common, followed by biphasic 72/319 (21.8%) and sarcomatoid 45/319 (13.6%); histology could not be confirmed in 10 patients. Calretinin expression was detected in 246 of the 324 (76%) evaluable patients and high expression was associated with epithelioid histology (p < 0.0001). Caveolin-1 was expressed in 298 (94%) of 317 evaluable patients which was much higher compared to its expression in a cohort of lung adenocarcinomas (8/58, 13.7%). However, no association with histology was found (p = 0.409). When taken as a continuous variable, calretinin expression was found to be an independent predictor of survival, alongside histology, neutrophil-lymphocyte ratio, weight loss and stage. No prognostic value was demonstrable for caveolin-1 expression and calretinin/caveolin-1 ratio. There was no relationship between calretinin and caveolin-1 expression. In MM, increased calretinin expression is associated with epithelioid histology and better survival. Caveolin-1 is a sensitive MM marker and is expressed in a high proportion of cases but lacks association with histology and survival.en
dc.language.isoeng-
dc.subjectCalretininen
dc.subjectcaveolin-1en
dc.subjectimmunohistochemistryen
dc.subjectmesotheliomaen
dc.titleCalretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.en
dc.typeJournal Articleen
dc.identifier.journaltitlePathologyen
dc.identifier.affiliationAnatpath, Gardenvale, Vic, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Vic, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pathology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Thoracic Surgery, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Olivia-Newton John Cancer and Wellness Centre, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Epidemiology and Preventive Medicine, Monash University, Vic, Australiaen
dc.identifier.affiliationGarvan Institute of Medical Research, NSW, Australiaen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Vic, Australiaen
dc.identifier.doi10.1016/j.pathol.2016.08.003en
dc.type.contentTexten
dc.identifier.pubmedid27780599-
dc.type.austinJournal Article-
local.name.researcherAsadi, Khashayar
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptThoracic Surgery-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptPathology-
crisitem.author.deptThoracic Surgery-
crisitem.author.deptThoracic Surgery-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

64
checked on Dec 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.